Sunitinib Treatment
Sunitinib is an oral, small-molecule, multi-targeted kinase Inhibitor in first-line treatment of advanced renal cell carcinoma, and is approved in imatinib intolerant and imatinib refractory gastrointestinal stromal tumors. Fatigue and asthenia are among the most common symptoms experienced by cancer patients in sunitinib treatment, comprising pathologic tiredness, muscle weakness, poor endurance, and impaired motor and …
